ICH E6 is the harmonized GCP guideline adopted by FDA, EMA, PMDA, and other regulators. The R3 revision (in effect 2025) emphasizes proportionate, risk-based quality management, fit-for-purpose documentation, and modern trial designs including decentralized elements.